Cancer is one of the most common causes of death in the world and results in a serious problem to global health[@b1][@b2]. Despite advances in treatment for cancer, the prognosis remains unsatisfied[@b3]. Thus, exploring the methods of early detection and prevention are indispensable. Currently, gene-environment interactions have been thought to be main determinant of individual risk for diseases including cancer[@b4]. Genes decide the susceptibility of individual to environment and environmental factors often damage the DNA in turn. If the host DNA repair system does not perform their functions well in repairing such destructive DNA, it might alter the stability of genome and lead to carcinogenesis. Thus, the DNA repair ability plays a critical role in maintaining the stability of human genome.

*LIG4* gene, located on human chromosomes 13q33-34, encodes an ATP-dependent DNA ligase that joins single-strand breaks in a double-stranded polydeoxynucleotide in an ATP-dependent reaction[@b5]. The DNA ligase IV is the crucial enzyme to for completing the non-homologous end joining (NHEJ) by forming a complex together with X-ray repair cross complementing protein 4 (XRCC4) for a final ligation of the break in an ATP-dependent step[@b6][@b7]. Therefore, the loss or variant of *LIG4* is supposed to contribute to genomic instability and tumorigenesis.

According to supposition mentioned above, we reviewed the related studies concerning of *LIG4* variants and susceptibility of tumor. Then, we found that numerous studies investigated this issue, however, the conclusions are inconsistent. To obtain a comprehensive conclusion, we carried out a meta-analysis to systematically evaluate the relevance of *LIG4* genetic variants with susceptibility of cancer.

Results
=======

Identification of relevant studies
----------------------------------

A total of 167 papers were indentified from the databases as we described above. After deleting the duplications, 111 papers were left. Then we estimated the rest articles and 72 articles were discarded because of irrelevance with this issue. And one other potential eligible paper was obtained by screening the references of reviews. Of the remains 40 papers, one article was excluded for animal study[@b8]; six papers were reviews[@b9][@b10][@b11][@b12][@b13][@b14]. Following this, two papers were concerned with prognosis[@b15][@b16], eight articles without detailed data for further evaluation[@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24]. Besides, six papers estimated *LIG4* polymorphism but not T9I or D501D[@b25][@b26][@b27][@b28][@b29][@b30]. Finally, a total of 17 studies with case-control design met the inclusion and exclusion criteria in this meta-analysis[@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47]. Of these 17 articles (one article included both rs1805386 and rs1805388), there were five articles with six studies for rs1805386, 13 articles with 15 studies for rs1805388. The flow diagram of searching process was shown in [Figure 1](#f1){ref-type="fig"}.

Characteristics of included studies
-----------------------------------

Of these included articles, one article[@b42] with three caner types were separated as three independent studies and three articles[@b35][@b39][@b45] concluded rs1805386 and rs1805388. Noticeably, in the relevant articles, two articles[@b19][@b24] did not find the polymorphism of rs1805386 and another article[@b45] did supply with insufficient data for rs1805386 but for rs1805388. Thus, in the end, there were five articles with six studies for rs1805386, 13 articles with 15 studies for rs1805388 polymorphism.

Then, we established a database concerning of the information extracted from each included paper. Summaries of these studies were presented in [Table 1](#t1){ref-type="table"} which included the first author\'s surname, publication year, ethnicity, country, number and characteristics of cases and controls, and other relevant information.

Meta-analysis results
---------------------

### rs1805386

We found that there was no obvious relevance of *LIG4* D501D variants with overall cancer risk (homozygous: OR = 0.97, 95% CI = 0.59--1.59, *P* = 0.907; recessive: OR = 0.96, 95% CI = 0.88--1.06, *P* = 0.434; dominant: OR = 0.99, 95% CI = 0.61--1.60, *P* = 0.952; allele: OR = 0.95, 95% CI = 0.87--1.03, *P* = 0.229) ([Table 2](#t2){ref-type="table"}). In the subgroup analysis stratified by cancer types, no statistically significant relations were found for breast cancer and ovarian cancer (The data were not shown).

### rs1805388

As shown in [Table 2](#t2){ref-type="table"} and [Figure 2](#f2){ref-type="fig"}, there was no relevance of *LIG4* T9I variants with overall cancer risk (homozygous: OR = 0.84, 95% CI = 0.55--1.27, *P* = 0.401; recessive: OR = 0.94, 95% CI = 0.81--1.09, *P* = 0.434; dominant: OR = 0.85, 95% CI = 0.58--1.25, *P* = 0.410; allele: OR = 0.93, 95% CI = 0.80--1.07, *P* = 0.306). However, in the subgroup analysis, a statistically significant association was found among Caucasians (homozygous: OR = 0.61, 95%CI = 0.40--0.91, *P* = 0.016; recessive: OR = 0.86, 95% CI = 0.77--0.97, *P* = 0.016; dominant: OR = 0.63, 95% CI = 0.42--0.94, *P* = 0.023; allele: OR = 0.84, 95%CI = 0.74--0.95, *P* = 0.004).

Heterogeneity and sensitivity analysis
--------------------------------------

Heterogeneities were observed among several studies for *LIG4* D501D polymorphism and overall cancer susceptibility (homozygous: *P* = 0.044; dominant: *P* = 0.048;) and T9I (homozygous: *P* \< 0.001; recessive: *P* \< 0.001; dominant: *P* \< 0.001; allele: *P* \< 0.001). Thus, we selected the random-effect models to generate pooled ORs and corresponding 95% CIs for these models. On the other hand, no heterogeneity was observed among the other two models for D501D (recessive: *P* = 0.520; allele: *P* = 0.218) and the fixed-effect models were performed to generate ORs and 95% CIs for them. The sensitivity analysis suggested that no obvious changes were observed for the pooled ORs when single investigation was excluded respectively (data were not shown).

Publication bias
----------------

The shape of the funnel plot showed that no evidence of asymmetry was observed in the current meta-analysis by Egger\'s test for T9I (homozygous: *P* = 0.530; recessive: *P* = 0.919; dominant: *P* = 0.482; allele: *P* = 0.585) and D501D (homozygous: *P* = 0.501; recessive: *P* = 0.073; dominant: *P* = 0.499; allele: *P* = 0.451), which suggested that there were no significant publication bias among all these studies.

Trial sequential analysis (TSA)
-------------------------------

Fifteen trials (11180 subjects) were used to investigate the relevance of rs1805388 gene polymorphism with cancer susceptibility. Using the TSA (taking the data of dominant model for example), the required information size is 21516 subjects to demonstrate the issue ([Figure 3A](#f3){ref-type="fig"}). Until now, the cumulative z-curve has not crossed the trial monitoring boundary before reaching the required information size, indicating that the cumulative evidence is insufficient and further trials are necessary. However, the cumulative z-curve crossed with TSA monitoring boundary when we performed the sub-analysis based on the ethnicity, confirming that rs1805388 is associated with a slightly decreased cancer risk among Caucasians and further relevant trials are unnecessary ([Figure 3B](#f3){ref-type="fig"}). As for rs1805386, we chose the data of four models to perform TSA. The cumulative z-curve have crossed with TSA monitoring boundaries before the required information size is reached, indicating that the rs1805386 polymorphism is not a risk factor of cancer and no further trials are necessary (figures were not shown).

Discussion
==========

Genomic instability is an outstanding characteristic of cancer[@b48]. Numerous studies have demonstrated that tumor suppressor genes play a significant role in DNA double-strand break (DSB) repair and in maintenance of genomic stability; correspondingly, loss or mutation of such repair genes results in a shifty susceptibility for malignancies.

In eukaryotes, homologous recombination and NHEJ are two major pathways for DNA DSB repair and the latter is predominantly way in mammalian cells[@b49]. In the NHEJ process, LIG4, as a major functional protein, forms a complex with XRCC4 to perform the final rejoining step of NHEJ. Thus, the genetic variant of LIG4 might alter the repair capacity of DSB.

Previous investigation had demonstrated that polymorphisms in DNA repair genes might alter DNA repair capacity and thus contribute to cancer risk[@b50]. In 2002, Kuschel et al.[@b40] found that *LIG4* D501D polymorphism was associated with a decrease in breast cancer risk and Roddam et al.[@b42] found that *LIG4* T9I polymorphism may modulate predisposition to multiple myeloma. After these discoveries, a mass of investigations were performed to estimate the association between *LIG4* T9I and D501D polymorphisms and the susceptibility of various cancers. To our puzzled, the results are conflicting. Thus, we performed a meta-analysis to obtain a comprehensive conclusion.

To our knowledge, this is the first time to systematically estimate the associations between *LIG4* T9I and D501D polymorphisms and susceptibility of overall cancer. In this study, we found that rs1805386 and rs1805388 genetic variants had no relevance with overall cancer risk in homozygous, recessive, dominant and allele models. To further investigate the associations, we performed the subgroups analysis based on ethnicity and cancer types and found that rs1805388 variant is a decreased risk of cancers among Caucasians.

In order to make the conclusion more credible, we performed the publication bias analysis and sensitivity analysis according to Cochrane protocol. Funnel plots suggested that no obvious publication bias was observed. The sensitivity analysis indicated that the results are robust and no single study yield to obvious effects on the pooled ORs and the corresponding CIs. Besides, we performed the TSA and the results of TSA showed that the conclusions in this meta-analysis are robust.

However, several limitations in this meta-analysis should be noticed. Firstly, several studies had small sample sizes which might lessen the statistical power. Secondly, the heterogeneity was existed and thus we performed the random-effects model to obtain the wider CIs, which might weaken the reliability of conclusions. Thirdly, our results were based on unadjusted assessment of ORs, which might influence the results. Fourthly, we did not search the unpublished studies, which might miss the relevant studies. Besides, all data included in this study were from published investigations which were based on the current marker identification method of the 'one-step-clustering\'. This approach might tend to be 'passenger signals\' instead of 'drivers\' and bury the 'real\' cancer gene, which made the results less robust and accurate[@b51][@b52]. Based on the limitations mentioned above, the results should be considered with caution.

Overall, in spite of these limitations, this analysis reached a precise conclusion that *LIG4* D501D polymorphism has no obvious relevance with cancer risk and individual with *LIG4* T9I genetic variant has a decrease cancer risk among Caucasians. With the development of research methods, future studies focusing on a combinatorial use of the polygene markers and integrative network modules analysis, are necessary to make the conclusions more comprehensive.

Methods
=======

Search strategy
---------------

We searched the PubMed, Web of Science, Ovid and Embase databases without language limitations for all related papers using the following searching strategies: 1) *LIG4* or *LIG 4* or *ligase IV*, 2) polymorphism or variant or variation or allele or genotype, and 3) cancer or carcinoma or tumor or neoplasm. And the last research was updated on May 15, 2014. All searched studies were screened and their references were retrieved to obtain other related articles. Then we downloaded the relevant papers and further screened to identify potentially eligible studies.

Inclusion/exclusion criteria
----------------------------

Studies included in this studies had to meet the following inclusion criteria: (1) estimating the relevance of *LIG4* polymorphisms (rs1805386 and rs1805388) and cancer susceptibility; (2) case-control design; (3) sufficient data provided to assess odds ratios (ORs) and the corresponding confidence intervals (CIs); (4) when multiple publication from a particular research group reported data from overlapping samples, the study reporting the largest or latest dataset was included. Exclusion criteria: (1) review articles; (2) case reports, or case-only studies; (3) studies that estimated the risk of prognosis.

Data extraction
---------------

All data were independently reviewed and extracted from the included papers by two authors (S.X. and J.H.). Disagreements were solved by full discussion until a consensus was reached. The following characteristics were collected from each study: first author\'s surname, year of publication, ethnicity, country, cancer type, sample size, control source, matching contents, the Hardy-Weinberg equilibrium, genotype methods and genetic distribution of cases and controls. The subgroup analysis was performed by cancer type and ethnicity.

Statistical analysis
--------------------

All the data management and analysis for this meta-analysis were performed with STATA 11.0 software (Stata corporation, College Station, TX). The strength of association between rs1805386 and rs1805388 polymorphisms and cancer susceptibility was estimated by calculating OR with the corresponding 95% CI. In order to calculate heterogeneity of studies, the Chi-Square test was used and significance was set at *P* value less than 0.05 level[@b53]. If the study was found to be heterogeneous (*P* \> 0.10 for the Q-test), the fixed-effects model (the Mantel-Haenszel method) was performed to calculate the combined OR[@b54]. Otherwise, a random effect model (the DerSimonian and Laird method) was used to estimate the pooled OR[@b55]. In addition, the heterogeneity was also quantified with *I^2^* statistics. The *I^2^* value ranges from 0 to 100% and a larger *I^2^* value indicating a greater heterogeneity[@b56]. The funnel plot was used to test the potential publication bias, and the funnel plot asymmetry was estimated by Egger\'s linear regression[@b57]. Sensitivity analyses were performed to identify the influence of the each study on the combined ORs and 95% CI.

Trial sequential analysis (TSA)
-------------------------------

According to Cochrane Handbook for systematic reviews of interventions, meta-analyses and systematic reviews are considered to be the best available evidence if all available trials are included. However, 'the best available evidence\' might not be equal to 'strong evidence\' or 'sufficient evidence\'. It is well-known that meta-analysis may cause random errors in the series of sparse data and reduplicative testing on accumulating data. Based on these problems mentioned above, we applied the TSA to minimize the random errors and increase the robustness of conclusions[@b58][@b59]. In our study, we planned to calculate the required information size and estimate how many patients would be necessary to make a robust conclusion[@b58]. The required information size was based on the assumption of a plausible relative risk of 10% with low risk bias, and we adopted the risks for a type I error (α) of 5%, a type II error (β) of 20%[@b58]. Based on required information size and risk for type I and type II errors TSA monitoring boundaries were built. If a TSA monitoring boundary is crossed with Z-curve before the required information size is reached, robust evidence might have been confirmed and further trials are unnecessary. Otherwise, it is necessary to continue doing trials.
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###### Characteristics of studies included in this meta-analysis

  Surname          Year     Country      Ethnicity           Cancer type               Control source      Genotyping methods   Cases/Control                 D. Case                             D. Control                HWE
  --------------- ------ -------------- ----------- ------------------------------ ---------------------- -------------------- --------------- ------------------------------------- ------------------------------------ -------
  rs1805388                                                                                                                                                                                                                   
  Roddam           2002        UK        Caucasian   acute lymphoblastic leukemia            NA                   PCR              70/220                     0/21/49                             13/58/149                0.03
  Roddam           2002        UK        Caucasian             lymphoma                      NA                   PCR              362/220                   7/108/247                            13/58/149                0.03
  Roddam           2002        UK        Caucasian         multiple myeloma                  NA                   PCR              269/220                   4/61/204                             13/58/149                0.03
  Fu               2003      China         Asian            breast cancer           socioeconomic status       MassARRAY           253/376                  16/100/137                            28/150/198               0.955
  Garcia-Closas    2006       USA        Caucasian          breast cancer                   Age                  Taqman           1316/1043                 57/339/920                            42/277/724               0.199
  Hill             2006       USA        Caucasian       non-Hodgkin lymphoma           Age, gender              Taqman           1110/931                  18/300/792                            28/275/628               0.75
  Wu               2006      China         Asian            bladder cancer              Age, gender             PCR-RFLP           606/593                  24/168/414                            15/194/384               0.099
  Andreae          2007     Germany      Caucasian   acute lymphoblastic leukemia       Age, gender              DHPLC             107/104                    3/19/85                              3/33/68                 0.673
  Werbrouck        2008     Belgium      Caucasian       head and neck cancer           Age, gender             PCR-RFLP           152/157                   3/30/119                              8/44/105                0.242
  Tseng            2009      Taiwan        Asian             lung cancer                Age, gender               PCR              149/152                   20/62/67                              12/55/85                0.464
  Li               2009       USA        Caucasian        pancreatic cancer             Age, gender              Taqman            723/776                  23/197/503                            29/208/539               0.117
  Gomes            2010     Portugal     Caucasian          thyroid cancer              Age, gender          Real-Time PCR         109/217                    4/22/83                              5/54/158                0.879
  Al-Hadyan        2012   Saudi Arabia     Asian         head and neck cancer               Age                   PCR              156/251                   0/24/132                              4/31/216                0.029
  Salagovic        2012     Slovakia     Caucasian             lymphoma                      NA                   PCR              107/127                    1/26/80                              2/32/93                 0.688
  Zhao             2013      China         Asian                glioma                  Age, gender               PCR              384/384                  49/172/163                            20/142/222               0.659
  rs1805386                                                                                                                                                                                                                   
  Kuschel          2002     Germany      Caucasian          breast cancer                    NA                   PCR             1440/2016                 20/322/914                           50/492/1248               0.857
  Han              2004       USA        Caucasian          breast cancer                 Age, BMI               Taqman           977/1266                  22/274/681                            32/360/874               0.48
  Garcia-Closas    2006       USA        Caucasian          breast cancer                   Age                  Taqman           1338/1057                 55/379/904                            34/309/714               0.934
  Jakubowska       2010     Germany      Caucasian          breast cancer                    NA                   PCR              319/290      112[\*](#t1-fn2){ref-type="fn"}/207   94[\*](#t1-fn2){ref-type="fn"}/196    NA
  Jakubowska       2010     Germany      Caucasian          ovarian cancer                   NA                   PCR              145/280       54[\*](#t1-fn2){ref-type="fn"}/91    92[\*](#t1-fn2){ref-type="fn"}/188    NA
  Assis            2010     Portugal     Caucasian          ovarian cancer                   NA              Real-Time PCR         126/198                    7/36/83                              5/60/133                0.562

NA: not available; D.: distribution;

\*: homozygous variants + heterozygous variant (CC + TC); HWE: Hardy-Weinberg Equilibrium.

###### Relevance of rs1805388 and rs1805386 with cancer risk in this Meta-analysis

                              Homozygous          Recessive       Dominant        Allele                                                                                      
  ----------- ----------- ------------------- ------------------ ---------- ------------------- ------- ------ ------------------- ------- ------ ------------------- ------- ------
  For T9I      TT vs. CC   (TT + TC) vs. CC    TT vs. (TC + CC)   T vs. C                                                                                                     
  All          5873/5771   0.84 (0.55--1.27)        0.000          0.704     0.94 (0.81--1.09)   0.000   65.6   0.85 (0.58--1.25)   0.000   65.3   0.93 (0.80--1.07)   0.000   73.7
  Ethnicity                                                                                                                                                                      
  Asian        1941/1991   1.57 (0.83--2.98)        0.011          0.693     1.20 (0.85--1.70)   0.001   80.0   1.50 (0.88--2.56)   0.047   58.6   1.18 (0.88--1.59)   0.000   81.9
  Caucasian    3932/3780   0.61 (0.40--0.91)        0.064          0.443     0.86 (0.77--0.97)   0.238   22.3   0.63 (0.42--0.94)   0.068   43.6   0.84 (0.74--0.95)   0.108   37.6
  For D501D    CC vs. TT   (CC + CT) vs. TT    CC vs. (CT + TT)   C vs. T                                                                                                     
  All          4161/4881   0.97 (0.59--1.59)        0.044           63.1     0.96 (0.88--1.06)   0.520   0.0    0.99 (0.61--1.60)   0.048   62.1   0.95 (0.87--1.03)   0.218   32.4
